With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Revolution Medicines surged on AbbVie buyout rumors but pulled back after denial. Learn what's next for RVMD stock and why it ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing a novel and differentiated inhaled therapeutic ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

In-office treatments are expensive, time-consuming, and realistically not something most of us can book as often as ...

Columbina is a five-star Hydro character in Genshin Impact. Wielding a Catalyst, Columbina is a powerful support unit that ...

Dr. Shereene Idriss, board-certified dermatologist and the founder of Idriss Dermatology in New York City: Number one is ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...